Simplify diabetes management for your patients
Australia’s first tubeless hybrid closed loop system that integrates with the leading sensor brands∞, for your patients with type 1 diabetes (T1D) aged 2 years and older.
Compatible with the leading sensor brands**
- Your patients can experience the freedom of automated insulin delivery with their preferred glucose sensor – Omnipod 5 is compatible with Dexcom G6, Dexcom G7 and FreeStyle Libre 2 Plus Sensors.
- SmartAdjust™ Technology adjusts basal insulin delivery, every five minutes, so you don’t have to. ** It proactively helps to correct highs and protect from lows.1,2
- Improved HbA1c and time in range across age groups vs prior therapy, while time in hypoglycaemia remained low1,2
The System
Controller + Pod + Sensor
The Algorithm Explained
SmartAdjust™ Technology
SmartAdjust™ technology adjusts basal insulin automatically No need to continuously fine-tune basal settings. The system uses recent total daily insulin history to adapt to changes throughout life like changes in weight, growth and aging.** Watch this short video to learn more about the technology and how it works.
Arrange a meeting with an Omnipod® representative
Do you have questions about Omnipod? Our team is happy to provide you with the information you need and help you to determine which of your patients could best benefit from Omnipod.
Simple for them
Improved results with no more multiple daily injections, tubing or fingersticks.3
Your patients can enjoy the benefits of Omnipod 5:
- Discreet
- Tubeless
- Waterproof**
- No need for patients to disconnect for daily activities
- Patients previously on MDI switching to Omnipod 5, have seen success achieving a time in range of 70.8% at an average target of 110mg/dL (6.1 mmol/L)4
Simple to start
Omnipod 5 Resources for your Patients
All of the resources, all in one place. Visit our resources page for User Guides, How-to-Videos, FAQs and more.
Support more patients to try Omnipod
For additional patients, Pod Experience Kits can be ordered directly from Omnipod to try the comfort and convenience of the Pod. Each kit includes a needle-free Pod that does not deliver insulin. (Controller is not included)
Get in touch!
If you need more information, reach out to us. Your local Omnipod representative can answer questions, provide materials and support your patient conversations.
We believe in freedom of choice
For people with type 1 diabetes, we know that choosing an insulin pump for the first time or changing from an existing one is not an easy option
We are also aware that four-year warranties on insulin pumps are typically viewed as ‘lock-in’ periods and a potential barrier to patient choice.
That is why we strive to take steps to facilitate flexibility and reduce ‘lock-in’ periods with the Omnipod® 5 System.
Request a call-back by your local Omnipod® representative to understand more.
Arrange a meeting with an Omnipod® representative
Do you have questions about Omnipod? Our team is happy to provide you with the information you need and help you to determine which of your patients could best benefit from Omnipod.
(ST) phase followed by a 3-month Omnipod 5 hybrid closed-loop (HCL) phase. Mean time in range (3.9-10.0 mmol/L or 70-180mg/dL) in adults/adolescents as
measured by CGM: ST = 64.7%, 3-mo Omnipod 5 = 73.9%, P<0.0001. Mean time in range (3.9-10.0 mmol/L or 70-180mg/dL) in children as measured by CGM: ST = 52.5%, 3-mo Omnipod 5 = 68.0%, P<0.0001. Mean HbA1c: ST vs. Omnipod 5 use in adults/adolescents (14-70 yrs) and children (6-13.9 yrs), respectively (7.16% vs 6.78% or 55 mmol/mol vs. 51 mmol/mol, P<0.0001; 7.67% vs 6.99% or 60mmol/mol vs 53 mmol/mol), P<0.0001). Median time in hypoglycemic range (<3.9 mmol/L) as measured by CGM in adults/adolescents and children ST vs. 3-mo Omnipod 5: 2.0% vs. 1.1%, P<0.0001; 1.4% vs. 1.5%, P 0.8153, respectively. Study funded by Insulet. Study materials provided by Insulet.
2. Sherr J. et al. Diabetes Care. 2022; 45:1907-1910. Single-arm multicenter clinical trial in 80 pre-school children (aged 2-5.9 yrs) with T1D. Study included a 14-day standard therapy (ST) phase followed by a 3-month AID phase with Omnipod 5 system. Mean time in hyperglycemic range (>10.0 mmol/L) as measured by CGM in children ST vs. 3-mo Omnipod 5: 39.4% vs 29.5%, P<0.0001, respectively. Median time in hypoglycemic range (<3.9 mmol/L) as measured by CGM in children ST vs. 3-mo Omnipod 5: 2.19% vs. 1.94%, P = 0.0204. Study funded by Insulet. Study materials provided by Insulet.
3. Fingersticks required for diabetes treatment decisions if symptoms or expectations do not match readings.
4. Forlenza G, et al. Diabetes Technol Ther (2024). 6,525 Omnipod 5 users in the United States with type 1 diabetes at the Target Glucose of 110 mg/dL (6.1 mmol/L) who utilized MDI as prior therapy had a time in range of 70.8% and time below range of 0.96%. Omnipod 5 results based on users with ≥90 days CGM data, ≥75% of days with ≥220 readings available.
*The Pod has an IP28 rating for up to 7.6 metres for up to 60 minutes. The Omnipod 5 Controller is not waterproof. Please consult sensor manufacturer user guide for sensor waterproof rating.
** When used in automatic mode with a compatible CGM, the Omnipod 5 System makes adjustments to insulin delivery every 5 minutes based on the user's current CGM value, glucose values predicted 60 minutes in the future, glucose trend, and past insulin delivery to bring glucose to a user defined target.
† Fingerpricks required for diabetes treatment decisions if symptoms or expectations do not match readings.
Important Safety Information: The Omnipod 5 Automated Insulin Delivery System is a single hormone insulin delivery system intended to deliver U-100 insulin subcutaneously for the management of type 1 diabetes in persons aged 2 and older requiring insulin.
The Omnipod 5 System is intended to operate as an automated insulin delivery system when used with compatible Continuous Glucose Monitors (CGM). When in automated mode, the Omnipod 5 system is designed to assist people with type 1 diabetes in achieving glycaemic targets set by their healthcare providers. It is intended to modulate (increase, decrease or pause) insulin delivery to operate within predefined threshold values using current and predicted CGM values to maintain blood glucose at variable target glucose levels, thereby reducing glucose variability. This reduction in variability is intended to lead to a reduction in the frequency, severity, and duration of both hyperglycaemia and hypoglycaemia.
The Omnipod 5 System can also operate in a manual mode that delivers insulin at set or manually adjusted rates.
The Omnipod 5 System is intended for single patient use. The Omnipod 5 System is indicated for use with NovoLog®/NovoRapid®, Humalog® / Liprolog®, Admelog® / Insulin lispro Sanofi®, Trurapi® / Insulin aspart Sanofi®, and Kirsty® U-100 insulin.
Warning: SmartAdjust™ technology should NOT be used by anyone under the age of 2 years old. SmartAdjust™ technology should also NOT be used in people who require less than 5 units of insulin per day as the safety of the technology has not been evaluated in this population.
The Omnipod® 5 System is NOT recommended for people who are unable to monitor glucose as recommended by their healthcare provider, are unable to maintain contact with their healthcare provider, are unable to use the Omnipod® 5 System according to instructions, are taking hydroxyurea and using a Dexcom Sensor as it could lead to falsely elevated CGM values and result in over-delivery of insulin that can lead to severe hypoglycaemia, and do NOT have adequate hearing and/or vision to allow recognition of all functions of the Omnipod® 5 System, including alerts, alarms, and reminders. Device components including the Pod, CGM transmitter, and CGM sensor must be removed before Magnetic Resonance Imaging (MRI), Computed Tomography (CT) scan, or diathermy treatment. In addition, the Controller and smartphone should be placed outside of the procedure room. Exposure to MRI, CT, or diathermy treatment can damage the components.